Computational Models for Identifying Potential P-Glycoprotein Substrates and Inhibitors
- 8 December 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 3 (1) , 33-44
- https://doi.org/10.1021/mp050071a
Abstract
Multidrug resistance mediated by ATP binding cassette (ABC) transporters such as P-glycoprotein (P-gp) represents a serious problem for the development of effective anticancer drugs. In addition, P-gp has been shown to reduce oral absorption, modulate hepatic, renal, or intestinal elimination, and restrict blood−brain barrier penetration of several drugs. Consequently, there is a great interest in anticipating whether drug candidates are P-gp substrates or inhibitors. In this respect, two different computational models have been developed. A method for discriminating P-gp substrates and nonsubstrates has been set up based on calculated molecular descriptors and multivariate analysis using a training set of 53 diverse drugs. These compounds were previously classified as P-gp substrates or nonsubstrates on the basis of the efflux ratio from Caco-2 permeability measurements. The program Volsurf was used to compute the compounds' molecular descriptors. The descriptors were correlated to the experimental classes using partial least squares discriminant analysis (PLSD). The model was able to predict correctly the behavior of 72% of an external set of 272 proprietary compounds. Thirty of the 53 previously mentioned drugs were also evaluated for P-gp inhibition using a calcein-AM (CAM) assay. On the basis of these additional P-gp functional data, a PLSD analysis using GRIND-pharmacophore-based descriptors was performed to model P-gp substrates having poor or no inhibitory activity versus inhibitors having no evidence of significant transport. The model was able to discriminate between 69 substrates and 56 inhibitors taken from the literature with an average accuracy of 82%. The model allowed also the identification of some key molecular features that differentiate a substrate from an inhibitor, which should be taken into consideration in the design of new candidate drugs. These two models can be implemented in a virtual screening funnel. Keywords: P-glycoprotein; structure−property relationships; SPR; 3D pharmacophore, in silico screening; P-gp substrates; P-gp inhibitors; Volsurf; GRIND; Caco-2 permeability, efflux ratio; calcein-AM assay; CAM assayKeywords
This publication has 32 references indexed in Scilit:
- A Pharmacophore Hypothesis for P-Glycoprotein Substrate Recognition Using GRIND-Based 3D-QSARJournal of Medicinal Chemistry, 2005
- Predicting P-glycoprotein substrates by a quantitative structure–activity relationship modelJournal of Pharmaceutical Sciences, 2004
- Conformer- and Alignment-Independent Model for Predicting Structurally Diverse Competitive CYP2C9 InhibitorsJournal of Medicinal Chemistry, 2004
- An atomic detail model for the human ATP binding cassette transporter P‐glycoprotein derived from disulphide cross‐ linking and homology modelingThe FASEB Journal, 2003
- Calcein accumulation as a fluorometric functional assay of the multidrug transporterPublished by Elsevier ,2002
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999
- Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assayAnti-Cancer Drugs, 1996
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Modulation of multidrug resistance by verapamil or mdr1 anti‐sense oligodeoxynucleotide does not change the high susceptibility to lymphokine‐activated killers in mdr‐resistant human carcinoma (LoVo) lineInternational Journal of Cancer, 1990
- A computational procedure for determining energetically favorable binding sites on biologically important macromoleculesJournal of Medicinal Chemistry, 1985